» Articles » PMID: 24971825

Alterations in the Serotonin System in Schizophrenia: a Systematic Review and Meta-analysis of Postmortem and Molecular Imaging Studies

Overview
Date 2014 Jun 28
PMID 24971825
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Serotonergic dysfunction is thought to contribute to the pathophysiology of schizophrenia but the evidence has not been systematically synthesised before. We therefore systematically reviewed postmortem and in vivo molecular imaging studies of serotonin function in schizophrenia. We identified fifty relevant studies investigating eight different serotonin receptor systems in a total of 684 patients and 675 controls. Meta-analysis of postmortem studies found an elevation in prefrontal 5-HT1A receptors with a moderate to large effect size (N=8, 85 patients and 94 controls, SMD=0.60; CI: 0.17-1.03; p=0.007) and a reduction with a large effect size in prefrontal 5-HT2A receptors (N=8, 168 patients and 163 controls, SMD=-0.73; CI: -1.33, -0.12; p=0.019) in schizophrenia vs healthy controls. The evidence for alterations in serotonin transporter availability or other serotonin receptors (5-HT1B; 5-HT1D; 5-HT3; 5-HT4; 5-HT7) is limited. There are fewer studies investigating 5-HT receptors in schizophrenia with neuroimaging. Findings indicated possible 5-HT alterations at psychosis onset, although due to the limited number it was not possible to combine studies in a meta-analysis. Further in vivo studies, particularly in drug naive patients using radiotracers that can index high affinity states, will help determine if the postmortem findings are primary or secondary to other factors.

Citing Articles

Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds.

Biso L, Carli M, Scarselli M, Longoni B Biomedicines. 2025; 13(1).

PMID: 39857669 PMC: 11763187. DOI: 10.3390/biomedicines13010085.


Epigenetic Control in Schizophrenia.

DAddario C, Di Bartolomeo M Subcell Biochem. 2025; 108():191-215.

PMID: 39820863 DOI: 10.1007/978-3-031-75980-2_5.


Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.

Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X Int J Mol Sci. 2024; 25(19).

PMID: 39408997 PMC: 11477438. DOI: 10.3390/ijms251910668.


Abnormal interhemispheric functional cooperation in schizophrenia follows the neurotransmitter profiles.

He K, Hua Q, Li Q, Zhang Y, Yao X, Yang Y J Psychiatry Neurosci. 2023; 48(6):E452-E460.

PMID: 38123242 PMC: 10743641. DOI: 10.1503/jpn.230037.


Schizophrenia: from neurochemistry to circuits, symptoms and treatments.

Howes O, Bukala B, Beck K Nat Rev Neurol. 2023; 20(1):22-35.

PMID: 38110704 DOI: 10.1038/s41582-023-00904-0.